Glaxosmithkline Share News (GSK)

LONDON MARKET OPEN: Flutter Entertainment rises but 888 disappoints

(Alliance News) - Stock prices in London opened mixed on Friday with Flutter Entertainment leading the FTSE 100, while pharmaceutical companies responded to market concerns about litigation over withdrawn heartburn treatment Zantac.

GSK, Sanofi and Haleon shares stabilise after Zantac litigation slump

LONDON, Aug 12 (Reuters) - Shares in GSK, Sanofi <SASY.PA and Haleon began to stabilise on Friday after the companies said that nothing material had changed regarding U.S. litigation focused on heartburn drug Zantac.

LONDON BRIEFING: Haleon, GSK, Pfizer and Sanofi respond on Zantac hit

(Alliance News) - Pfizer late Thursday said it has "significant defences" against Zantac litigation, while Haleon revealed it is "not a party" to any claims.

GSK to 'vigorously defend' Zantac claims; Haleon says not a party to claims

(Sharecast News) - GlaxoSmithKline said on Friday that it would "vigorously defend" all claims related to its discontinued heartburn drug Zantac.

TOP NEWS: Pfizer and Haleon distance themselves from Zantac litigation

(Alliance News) - Pfizer Inc late Thursday said it has "significant defences" against Zantac litigation, while Haleon PLC revealed it is "not a party" to any claims.

GSK, Sanofi and Haleon shares slump on Zantac litigation concerns

LONDON, Aug 11 (Reuters) - Shares in GSK, Sanofi and Haleon fell sharply on Thursday, following declines earlier this week, amid growing investor concerns about U.S. litigation focused on a heartburn drug that contained a probable carcinogen.

TOP NEWS: GSK, Sanofi say Zantac science backs defence over litigation

(Alliance News) - GSK PLC and Sanofi SA came out swinging on Thursday after sharp share price declines over Zantac litigation concerns.

GSK, Sanofi and Haleon shares slump on Zantac litigation concerns

LONDON, Aug 11 (Reuters) - Shares in GSK, Sanofi and Haleon fell sharply on Thursday, following declines earlier this week, amid growing investor concerns about U.S. litigation focused on a heartburn drug that contained a probable carcinogen.

European shares tick higher; Aegon shines on forecast raise

Aug 11 (Reuters) - European shares edged higher on Thursday after a strong rally in the previous session on signs of U.S. inflation cooling, while Aegon climbed after the Dutch insurer raised its full-year forecast.

FTSE 100 ends down as GSK slumps, eyes on GDP data

Aug 11 (Reuters) - Britain's main stock indexes closed lower on Thursday, with the blue-chip FTSE 100 hit by a slump in healthcare stocks and the midcap index slipping from two-month highs as the prospect of higher U.S. interest rates kept investors wary.

LONDON MARKET CLOSE: US inflation elation fades; GSK and Haleon weigh

(Alliance News) - Equities in London failed to sustain gains into Thursday despite further data showing price pressures may finally be easing in the US.

UK dividends calendar - next 7 days

GSK, Haleon, Sanofi slump amid Zantac litigation woes

(Sharecast News) - Shares in GlaxoSmithKline, Haleon and Sanofi tumbled on Thursday amid concerns about legal proceedings related to Glaxo's former blockbuster heartburn drug Zantac.

LONDON MARKET MIDDAY: Stocks down; Haleon and GSK hit by Zantac worry

(Alliance News) - Stock prices in London were mostly lower at midday on Thursday as a rally fuelled by cooling US inflation lost steam, while Walt Disney shares surged in New York after posting huge subscriber growth.

Haleon not a party to U.S. litigation focused on Zantac - spokesperson

LONDON, Aug 11 (Reuters) - Haleon - GSK's recently spun off consumer health unit - is not a party to the U.S. litigation focused on the heartburn medicine Zantac, a spokesperson told Reuters on Thursday.